Total Payments
$1,700
2024 Payments
$559.41
Companies
12
Transactions
46
Medicare Patients
15,225
Medicare Billing
$9.2M
Payment Breakdown by Category
Food & Beverage$1,680 (98.8%)
Other$19.73 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,680 | 45 | 98.8% |
| Entertainment | $19.73 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $434.86 | 7 | $0 (2024) |
| Genentech USA, Inc. | $310.57 | 13 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $139.74 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $128.04 | 5 | $0 (2023) |
| EyePoint Pharmaceuticals US, Inc. | $124.99 | 1 | $0 (2024) |
| Alimera Sciences, Inc. | $119.43 | 6 | $0 (2020) |
| Allergan Inc. | $117.03 | 1 | $0 (2017) |
| Optos, Inc. | $84.72 | 4 | $0 (2020) |
| Apellis Pharmaceuticals, Inc. | $79.03 | 3 | $0 (2024) |
| Genentech, Inc. | $71.78 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $559.41 | 6 | Astellas Pharma US Inc ($267.40) |
| 2023 | $380.89 | 11 | Astellas Pharma US Inc ($167.46) |
| 2022 | $127.46 | 3 | Genentech, Inc. ($71.78) |
| 2021 | $67.43 | 3 | Genentech USA, Inc. ($46.22) |
| 2020 | $116.41 | 6 | Alimera Sciences, Inc. ($46.15) |
| 2019 | $195.18 | 9 | Genentech USA, Inc. ($73.90) |
| 2018 | $100.08 | 5 | Alimera Sciences, Inc. ($40.48) |
| 2017 | $152.71 | 3 | Allergan Inc. ($117.03) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 10/30/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $111.56 | General |
| Category: Ophthalmology | ||||||
| 09/27/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: Ophthalmology | ||||||
| 08/23/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: Ophthalmology | ||||||
| 06/27/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $139.74 | General |
| Category: IMMUNOLOGY | ||||||
| 06/04/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Ophthalmology | ||||||
| 11/10/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $31.86 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/19/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $34.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/18/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $29.82 | General |
| 10/18/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $10.69 | General |
| 09/29/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $28.95 | General |
| Category: Ophthalmology | ||||||
| 08/23/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $34.27 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/21/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $33.00 | General |
| 07/20/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $93.95 | General |
| 05/26/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $30.81 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/07/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $22.80 | General |
| Category: Ophthalmology | ||||||
| 04/01/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $30.14 | General |
| Category: EYE CARE | ||||||
| 09/08/2022 | Genentech, Inc. | Lucentis (Biological), SUSVIMO, VABYSMO | Food and Beverage | In-kind items and services | $71.78 | General |
| Category: Ophthalmology | ||||||
| 08/29/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/27/2022 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $33.81 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/12/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Ophthalmology | ||||||
| 04/22/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/29/2021 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: Ophthalmology | ||||||
| 10/05/2020 | Alimera Sciences, Inc. | Iluvien (Drug) | Food and Beverage | Cash or cash equivalent | $21.81 | General |
| Category: Ophthalmology | ||||||
| 09/16/2020 | Optos, Inc. | P200DTx (Device), P200T, P200TE | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 4,416 | 40,607 | $10.2M | $2.8M |
| 2022 | 15 | 3,738 | 15,386 | $8.5M | $2.4M |
| 2021 | 14 | 3,559 | 12,399 | $7.5M | $2.3M |
| 2020 | 17 | 3,512 | 10,242 | $5.6M | $1.7M |
Total Patients
15,225
Total Services
78,634
Medicare Billing
$9.2M
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 197 | 4,316 | $3.0M | $777,836 | 25.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 145 | 25,680 | $2.0M | $744,044 | 37.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 109 | 780 | $1.6M | $538,523 | 34.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 404 | 1,957 | $1.4M | $198,032 | 13.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 420 | 1,759 | $304,307 | $137,645 | 45.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 928 | 1,284 | $312,012 | $134,302 | 43.0% |
| 92134 | Imaging of retina | Office | 2023 | 1,278 | 3,223 | $905,663 | $112,867 | 12.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 263 | 263 | $79,426 | $35,033 | 44.1% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 305 | 530 | $140,450 | $23,181 | 16.5% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 75 | 218 | $34,880 | $16,066 | 46.1% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 13 | 14 | $105,616 | $15,468 | 14.6% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 16 | 17 | $74,596 | $13,304 | 17.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 68 | 69 | $33,189 | $9,426 | 28.4% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 15 | 24 | $62,040 | $7,628 | 12.3% |
| 92250 | Photography of the retina | Office | 2023 | 141 | 207 | $88,596 | $6,625 | 7.5% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 19 | 20 | $31,000 | $4,556 | 14.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 20 | 246 | $13,500 | $207.56 | 1.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 139 | 1,278 | $2.6M | $910,722 | 35.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 169 | 3,935 | $2.8M | $875,088 | 31.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 356 | 1,782 | $1.3M | $179,639 | 13.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 343 | 1,544 | $267,112 | $118,563 | 44.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 735 | 1,031 | $250,533 | $104,902 | 41.9% |
| 92134 | Imaging of retina | Office | 2022 | 1,068 | 2,714 | $762,634 | $93,690 | 12.3% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 14 | 1,560 | $131,040 | $46,552 | 35.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 259 | 259 | $78,218 | $32,464 | 41.5% |
About Dr. Howard Chen, MD
Dr. Howard Chen, MD is a Ophthalmology healthcare provider based in Campbell, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699763748.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Howard Chen, MD has received a total of $1,700 in payments from pharmaceutical and medical device companies, with $559.41 received in 2024. These payments were reported across 46 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,680).
As a Medicare-enrolled provider, Chen has provided services to 15,225 Medicare beneficiaries, totaling 78,634 services with total Medicare billing of $9.2M. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Campbell, CA
- Active Since 10/12/2005
- Last Updated 11/20/2025
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1699763748
Products in Payments
- Izervay (Drug) $267.40
- Lucentis (Biological) $260.80
- OZURDEX (Drug) $147.17
- ACTHAR (Biological) $139.74
- Vabysmo (Drug) $99.68
- EYLEA (Biological) $96.18
- Syfovre (Drug) $79.03
- Iluvien (Drug) $78.95
- P200DTx (Device) $58.34
- BEOVU (Drug) $40.11
- EYLEA HD (Biological) $31.86
- Monaco (Device) $26.38
- VABYSMO (Drug) $21.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.